FDA pulls up Wockhardt’s UK unit

16 Nov 2010 Evaluate

The US drug regulator warned Wockhardt Ltd’s UK subsidiary CP Pharmaceuticals Ltd (currently known as Wockhardt UK Ltd) over violations of quality norms at its manufacturing plant in Wrexham.

Wockhardt acquired CP Pharma in 2003 for £10.85 million (Rs.82.46 crore then), key to expanding in Europe, a market which contributed 48% to total revenue in year ended March.

The FDA’s warning to the UK subsidiary found fault within three key areas—prevention of contamination, investigating the failure of production batches or components to meet specifications and assuring appropriate standards for product strength, quality and purity.

Wockhardt Share Price

1230.95 58.60 (5.00%)
22-Nov-2024 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1797.80
Dr. Reddys Lab 1213.90
Cipla 1486.30
Lupin 2069.95
Zydus Lifesciences 948.70
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.